share_log

This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside

This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside

這款治療眼病的鼻噴劑股票很有吸引力，有160%的潛在上漲空間
Benzinga Real-time News ·  2022/08/11 15:14
  • Chardan initiated coverage on Oyster Point Pharma Inc (NASDAQ:OYST) with a Buy rating and a price target of $22.
  • The lead product, Tyrvaya, was approved in October 2021 and generated $1.2 million in the first two months and $2.7 million in 1Q22, its first full quarter. 
  • The company will report Q2 earnings today after the market closes.
  • Chardan says that the prescriber base is bound to grow as Tyrvaya had an estimated commercial coverage for up to 95 million lives at the end of 1Q22, representing 52% of all U.S. commercial lives.
  • In addition, the company expects the Medicare Part D coverage to kick in 2023, further expanding patient access to Tyrvaya.
  • DED represents a large market, with an estimated addressable DED population in the U.S. of up to ~14 million.
  • Approved treatments include Novartis AG's (NYSE: NVS) Xiidra and AbbVie Inc's (NYSE: ABBV) Restasis.
  • The analyst notes that Tervaya's differentiated nasal spray with a quick onset of action could represent an attractive alternative.
  • Overall, Tyrvaya is well positioned to address the limitations of the SOC treatments.
  • Price Action: OYST shares are up 9.77% at $8.43 during the market session on the last check Thursday.
  • 查爾丹在以下日期開始覆蓋牡蠣點製藥公司(納斯達克：OYST)評級為買入，目標價為22美元。
  • 主導產品Tyrvaya於2021年10月獲得批准，在前兩個月創造了120萬美元的收入，在22年第一季度創造了270萬美元的收入，這是它的第一個完整季度。
  • 該公司將於今日收盤後公佈第二季度收益。
  • Chardan表示，處方藥的基礎肯定會增長，因為截至2012年第一季度末，Tyrvaya的商業保險估計高達9500萬人，佔美國所有商業生活的52%。
  • 此外，該公司預計聯邦醫療保險D部分覆蓋範圍將於2023年生效，進一步擴大患者獲得Tyrvaya的機會。
  • DED代表着一個巨大的市場，據估計，美國可尋址的DED人口高達約1400萬。
  • 批准的治療方法包括諾華製藥(紐約證券交易所股票代碼：NVS)西德拉和艾伯維公司(紐約證券交易所股票代碼：ABBV)Restasis。
  • 這位分析師指出，Tervaya的差異化噴鼻劑起效迅速，可能代表着一種有吸引力的替代方案。
  • 總體而言，Tyrvaya處於有利地位，可以解決SOC治療的侷限性。
  • 價格行動：週四尾盤，OYST股價上漲9.77%，至8.43美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論